Samedan
Samedan Ltd is a UK-based specialist pharmaceutical publisher producing five market-leading B2B magazines (EPC, ICT, IPT, EBR, PMPS) plus the Pharmafile and Pharmafocus brands and the FlyPharma conference series, serving pharma, biotech, and CRO decision makers globally through print, digital, and event channels.
- Company typePrivate
- Founded1996
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingDigital Commerce or Content
What Samedan does
Samedan Ltd is a London-based specialist B2B pharmaceutical publishing company founded in 1996. The company produces a portfolio of market-leading trade titles spanning the pharmaceutical development spectrum, including European Pharmaceutical Contractor (EPC), International Clinical Trials (ICT), Innovations in Pharmaceutical Technology (IPT), European Biopharmaceutical Review (EBR), and Pharmaceutical Manufacturing and Packing Sourcer (PMPS), supplemented by the Pharmafile magazine and directory, the Pharmafocus monthly newspaper, and the pharmafile.com and pharmafocus.com online platforms. In 2013, Samedan expanded through acquisition of the Pharmafile portfolio and in 2021 was itself acquired by PMGroup Worldwide Ltd, becoming part of the Datateam Media Group. The company also operates the FlyPharma conference series focused on pharmaceutical supply chain topics such as cold chain logistics, regulatory demands, and security technology.
Samedan monetizes its audience primarily through advertising and sponsorship across both print and digital surfaces, with each title reaching 10,000+ pharmaceutical industry decision makers. Revenue streams include magazine advertising (front cover positions, double page spreads, inside/outside covers, and digital sponsorship), ancillary web facilities (hyperlinks, banners, client news pages, and corporate profiles), and event sponsorship and delegate registration from FlyPharma conferences. Pricing is denominated in British pounds and structured around multi-year contracts, with a published rate card for ICT Magazine ranging from £950 for a front cover logo to £6,950 for outside back cover and digital sponsorship.
The underlying technology stack is built on a WordPress-based digital publishing platform integrated with standard third-party services including Google Analytics, Google reCAPTCHA, Google Fonts, Google Maps, and Vimeo for video content delivery. There is no disclosed proprietary technology, no AI/ML capability, and no native mobile application. Distribution combines quarterly print journals, bi-annual Pharmafile, monthly Pharmafocus, online platforms, social media presence across LinkedIn and title-specific X/Twitter accounts, RSS feeds, and the recurring FlyPharma conference series in Europe. The company's stated go-to-market is sales-led, with dedicated advertising executives assigned to each title conducting personalized outreach to pharmaceutical companies, biotech firms, CROs, and service providers.
Samedan firmographics
Firmographics- Name
- Samedan
- Legal name
- Samedan Ltd
- Website
- https://samedanltd.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Samedan Ltd is a UK-based specialist pharmaceutical publisher producing five market-leading B2B magazines (EPC, ICT, IPT, EBR, PMPS) plus the Pharmafile and Pharmafocus brands and the FlyPharma conference series, serving pharma, biotech, and CRO decision makers globally through print, digital, and event channels.
- Ownership category
- akta.pro rank
Samedan industry classification
Industry- Product category
- Pharmaceutical B2B Publishing and Trade Media
- NAICS
- Periodical Publishers (513120), Directory and Mailing List Publishers (51314)
- SIC
- Periodicals: Publishing Or Publishing & Printing (2721)
- akta.pro primary industry
- Business, Finance & Industry Trade Magazines (MPAJAEAM)
Keywords
Where Samedan is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Samedan business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Advertising and Sponsorship: Samedan generates primary revenue through advertising across its portfolio of pharmaceutical publications. Each title has dedicated advertising executives who sell advertising space to pharmaceutical companies, biotech firms, CROs, and industry service providers. Rates vary by publication size, placement, and format (print, digital sponsorship).
- Event Sponsorship and Registration: FlyPharma conferences generate revenue through delegate registrations and exhibitor/sponsor participation fees. The conferences cover pharma supply chain topics including cold chain innovations, regulatory demands, and security technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | ICT Magazine Advertising Rate Card |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Samedan product offering
Product offeringCore offering
Samedan produces and publishes a portfolio of specialist B2B pharmaceutical magazines (European Pharmaceutical Contractor, Pharmaceutical Manufacturing and Packing Sourcer, European Biopharmaceutical Review, Innovations in Pharmaceutical Technology, International Clinical Trials, Pharmafile, and Pharmafocus newspaper), available in print and digital formats. The company generates revenue by selling advertising space in these publications to pharmaceutical companies, biotechs, CROs, and service providers, and by hosting the FlyPharma conference series covering pharma supply chain topics including cold chain logistics, regulatory demands, and security technology.
Product overview
Samedan is a specialist pharmaceutical publishing company offering a portfolio of five market-leading print and digital publications spanning the pharmaceutical industry spectrum. The core offerings include: European Pharmaceutical Contractor (EPC) and International Clinical Trials (ICT) addressing clinical research and contract research; Innovations in Pharmaceutical Technology (IPT) covering pharmaceutical R&D technologies; Pharmaceutical Manufacturing and Packing Sourcer (PMPS) serving manufacturing and packaging sectors; and European Biopharmaceutical Review (EBR) focused on biopharmaceuticals. In 2013, Samedan expanded through acquisition of the Pharmafile portfolio, adding Pharmafile magazine and directory, Pharmafocus monthly newspaper, and Pharmafile.com online platform. The company also operates FlyPharma conferences for pharmaceutical logistics and supply chain professionals. All publications provide advertising platforms reaching 10,000+ key decision makers per title, featuring expert articles, news, case studies, and industry analysis for pharma professionals worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- European Pharmaceutical Contractor (EPC): Quarterly publication covering essential contract research issues between pharma companies and their CRO partners
- Pharmaceutical Manufacturing and Packing Sourcer (PMPS)
- European Biopharmaceutical Review (EBR)
- Innovations in Pharmaceutical Technology (IPT)
- International Clinical Trials (ICT)
- Pharmafocus
- Pharmafile
- Pharmafile.com
- FlyPharma
Products and services
- European Pharmaceutical Contractor (EPC) Published quarterly, EPC covers essential contract research issues between pharma companies and their CRO partners, providing strategic insight into the drug development industry for pharmaceutical executives and decision makers.
- Pharmaceutical Manufacturing and Packing Sourcer (PMPS) A specialist journal providing worldwide coverage of topics relating to the pharmaceutical manufacturing and packaging sector, designed for pharma, biotech, nutritional, and medical device professionals seeking sourcing services and improved efficiency.
- European Biopharmaceutical Review (EBR) A quarterly journal providing dedicated coverage of the European biopharmaceutical market, featuring in-depth articles, case studies, and reviews from specialists with hands-on biopharma industry experience.
- Innovations in Pharmaceutical Technology (IPT) Launched in 1997, IPT provides cutting-edge information on pharmaceutical R&D technologies, covering imaging and sensing, discovery and development, digital, manufacturing, and lab design for pharma R&D professionals.
- International Clinical Trials (ICT) A specialist journal providing global coverage of key topics pertinent to the clinical trials sector, published quarterly with EPC integrated as an inserted edition since late-2015, targeting clinical trial decision makers and CRO partners.
- Pharmafile First published in 1986, Pharmafile is a bi-annual publication facilitating collaboration and partnerships from drug development, clinical trials, and commercialisation, supported by an online directory.
- Pharmafocus Established in 1986, Pharmafocus is a monthly newspaper and one of the most respected news portals in the pharmaceutical and biotech industry, providing breaking stories and industry impact assessments.
- Pharmafile.com The online platform for exclusive pharmaceutical news, comment, contacts, services, jobs and events, home to Pharmafile and Pharmafocus online, serving pharmaceutical industry professionals.
- FlyPharma Europe Conference A conference series providing a platform for industry experts to discuss pharma supply chain topics including cold chain innovations, regulatory demands, security technology, and supply chain collaboration, with delegate registrations and exhibitor/sponsor participation.
Companies that use Samedan
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Samedan technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Samedan partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- PMGroup Worldwide LtdcoreSamedan Ltd was acquired by PMGroup Worldwide Ltd in 2021 and is now part of the Datateam Media Group. This acquisition positioned Samedan within a larger media group structure.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Samedan competitors and assessment
Company assessmentDirect peers
- PharmaTimes: UK-based B2B pharmaceutical media brand publishing a magazine and online news aimed at pharma professionals. Directly comparable to Samedan as a specialist pharma trade publisher with a print + digital model targeting overlapping pharma industry decision-makers.
- BioPharm International: B2B publication focused on biopharmaceutical development, manufacturing, and regulation. Closely comparable to Samedan's European Biopharmaceutical Review (EBR) in subject matter and audience.
- Fierce Pharma: Leading digital pharma news outlet covering industry, R&D, and policy. Comparable to Samedan's Pharmafocus and Pharmafile.com as a daily/breaking pharma news destination for industry professionals.
- Clinical Trials Arena: B2B publication covering clinical trials and CRO outsourcing. Directly comparable to Samedan's International Clinical Trials (ICT) and European Pharmaceutical Contractor (EPC) titles in topic and audience.
- Pharmaceutical Technology (Informa): Long-running B2B trade publication covering pharmaceutical development, manufacturing, and drug delivery — directly overlapping with Samedan's IPT, PMPS, and EBR titles in scope and audience.
Broad incumbents
- MJH Life Sciences: Large US-based B2B medical and pharma media group publishing brands like Pharmaceutical Executive and Drug Topics. Comparable as a multi-title pharma/healthcare media portfolio operator, though broader in scope than Samedan's pharma-only focus.
- Citeline (Informa Pharma Intelligence): Informa's pharma intelligence arm offering industry-leading data, news, and analysis (e.g., Trialtrove, Pharmaprojects, Pink Sheet). Comparable to Samedan as a major pharma-focused media and intelligence provider, but at much larger scale and with proprietary data products.
Emerging players
- Drug Discovery & Development: B2B publication focused on pharma R&D, drug discovery technologies, and lab innovation. Comparable to Samedan's Innovations in Pharmaceutical Technology (IPT) title in subject matter and R&D audience targeting.
- Outsourcing-Pharma.com: Digital B2B outlet covering pharma outsourcing, CRO/CDMO partnerships, and contract services. Comparable to Samedan's EPC publication in covering the pharma-CRO interface.
Others
- PMGroup Worldwide Ltd: Parent company of Samedan since 2021 and part of Datateam Media Group; operates adjacent pharmaceutical and packaging media titles (e.g., PMP News). Comparable as a pharma-industry B2B publisher within the same corporate family.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Samedan social profiles
Digital presenceSamedan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Samedan leadership team
Management profileNumber of profiles
Samedan funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Samedan M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Samedan
What does Samedan do?
Samedan produces and publishes a portfolio of specialist B2B pharmaceutical magazines (European Pharmaceutical Contractor, Pharmaceutical Manufacturing and Packing Sourcer, European Biopharmaceutical Review, Innovations in Pharmaceutical Technology, International Clinical Trials, Pharmafile, and Pharmafocus newspaper), available in print and digital formats. The company generates revenue by selling advertising space in these publications to pharmaceutical companies, biotechs, CROs, and service providers, and by hosting the FlyPharma conference series covering pharma supply chain topics including cold chain logistics, regulatory demands, and security technology.
Is Samedan a public or private company?
Samedan is a private company. It is classified as corporate owned and is currently operating.
When was Samedan founded?
Samedan was founded in 1996. It employs 11 to 50 people.
Where is Samedan based?
Samedan is headquartered in London, United Kingdom, in the Europe region.
How does Samedan make money?
Two revenue lines are on record. Advertising and Sponsorship is the primary driver. The others are event Sponsorship and Registration.
Who are Samedan's main competitors?
Direct peers on record are PharmaTimes, BioPharm International, Fierce Pharma, Clinical Trials Arena and Pharmaceutical Technology (Informa). Broad incumbents are MJH Life Sciences and Citeline (Informa Pharma Intelligence). Emerging players are Drug Discovery & Development and Outsourcing-Pharma.com. PMGroup Worldwide Ltd is listed as an others.
Does Samedan have an API?
No public API is recorded for Samedan.
What industry is Samedan in?
Samedan's product category is Pharmaceutical B2B Publishing and Trade Media. Its primary akta.pro industry code is MPAJAEAM, Business, Finance & Industry Trade Magazines. Its NAICS code is 513120 and its SIC code is 2721.